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All trans-retinoic acid (ATRA) is 
widely used to direct the 
differentiation of cultured stem 
cells.  When exposed to the 
pluripotent human embryonal 20 
carcinoma (EC) stem cell line, 
TERA2.cl.SP12, ATRA induces 
ectoderm differentiation and the 
formation of neuronal cell types. 
We have previously generated 25 
synthetic analogues of retinoic 
acid (EC23 and EC19) which also 
induce the differentiation of EC 
cells. Even though EC23 and EC 
19 have similar chemical 30 
structures, they have differing 
biochemical effects in terms of 
EC cell differentiation. EC23 
induces neuronal differentiation in 
a manner similar to ATRA, 35 
whereas EC19 directs the cells to 
form epithelial-like derivatives. 
Previous MALDI-TOF MS 
analysis examined the response of 
TERA2.cl.SP12 cells after 40 
exposure to ATRA, EC23 and 
EC19 and further demonstrated 
the similarly in the effect of 
ATRA and EC23 activity whilst 
responses to EC19 were very 45 
different. In this study, we show 
that Fourier Transform Infrared 
Micro-Spectroscopy FT-IRMS 
coupled with appropriate scatter 
correction and multivariate 50 
analysis can be used as an 
effective tool to further 
investigate the differentiation of 
human pluripotent stem cells and 
monitor the alternative affects 55 
different retinoid compounds have 
on the induction of differentiation. 
FT-IRMS detected differences 
between cell populations as early 
as 3 days of compound treatment. 60 
Populations of cells treated with 
different retinoid compounds 
could easily be distinguished from 
one another during the early 
stages of cell differentiation.  65 
These data demonstrate that FT-
IRMS technology can be used as a 
sensitive screening technique to 
monitor the status of the stem cell 
phenotype and progression of 70 
differentiation along alternative 
pathways in response to different 
compounds.  
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Introduction  
The use of stem cells in biomedical applications is currently an 
area of intense interest given the potential that stem cells offer in 
terms of a renewable source of material for the production of 
differentiated human tissues. There are however a number of 5 
challenges in stem cell biology and regenerative medicine which 
include: (i) maintenance of the stem cell phenotype; (ii) control of 
cell differentiation in a robust and reproducible manner; and (iii) 
ensuring the purity of cell populations.1,2 Monitoring the  
phenotype of stem cells and their differentiated progeny is 10 
therefore important. There are a number of approaches that utilise 
biological assays making use of biomarkers or labels to follow 
these processes.3,4 There are issues, however, with these 
approaches due to a limited number of known biomarkers, or the 
lack of biomarkers specificity.5-7 Approaches based on such 15 
biomarkers that use fluorescent or magnetic labels are therefore 
also shown to have drawbacks.8-10  
   Embryonal carcinoma (EC) cells are pluripotent stem cells 
derived from teracarcinomas and are considered to be the 
malignant counterparts of human embryonic stem (ES) cells. The 20 
EC stem cell line TERA2.cl.SP12 is one such line that has been 
derived,11 and used as a model for cellular development in 
humans.12 Cultures of TERA2.cl.SP12 have proven to be a robust 
model responsive to growth factors and compounds that interact 
with known biological pathways involved in the control of cell 25 
differentiation. 
   Naturally occurring retinoids play essential roles in a range of 
biological processes including embryonic development and are 
particularly important in the development of the central nervous 
system (CNS).13 For example, all trans-retinoic acid (ATRA) is 30 
the principal active form during early embryonic CNS 
development. Recently, we have designed and produced some 
synthetic analogues of ATRA, notably 4-(5,5,8,8-tetramethyl-
5,6,7,8-tetrahydronaphthalen-2-ylethynyl) benzoic acid (EC23) 
and 3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-35 
ylethynyl) benzoic acid (EC19) (Fig. 1).14 
 
 
 
 40 
 
 
 
 
Fig. 1 Molecular structures of the retinoid analogues ATRA, EC23 and 45 
EC19. 
 
We have previously reported that EC23 induces neural 
differentiation in a manner similar to ATRA, whereas EC19 
produces very few neurons and a large number of epithelial-like 50 
cells.14 At present, it is not entirely clear how relatively small 
structural changes in these types of small molecules effect the 
different development processes, and this is therefore an 
important and developing area of study. Recent proteomic 
profiling (MALDI-TOF MS matrix assisted laser desorption 55 
ionisation time of flight mass spectrometry) and identification of 
biomarkers of the stem cell response to retinoic acid and the 
synthetic retinoid analogues has been described and supports the 
previous findings into functional relationships.15 Of particular 
note is the fact that the results indicate that there is a subtle but 60 
significant difference in the response of TERA2.cl.SP12 cells to 
ATRA and synthetic compounds such as EC23, despite both 
molecules inducing the formation of neural cells.14 There is a 
need to be able to study more directly the structural and chemical 
effects that these types of compounds can elicit and to be able to 65 
monitor these effects over time to give greater differentiation 
between these developmental effects as a function of their 
structure. Furthermore, careful characterisation of pluripotent 
stem cells is required given their inherent ability for differentiate 
into multiple tissue types and form complex teratoma 70 
tumours.16,17  
   This has led to the suggestion that a non-invasive method that 
has no or minimal impact on the cell biology is required for 
monitoring the status of the stem cell phenotype or progression of 
their differentiation. A brief review of this area and its potential 75 
has recently been published,18 and a number of other studies have 
tackled the approach of studying stem cell differentiation in a 
label-free manner.19-22 One such method that is currently being 
developed is infrared micro-spectroscopy. Infrared spectroscopy 
of single cells was first demonstrated by Jamin et al.23 in the late 80 
1990s using synchrotron radiation generated infrared as the light 
source. This generated considerable interest in the field but real 
progress was hampered by severe scattering effects that distorted 
the spectra of the intact cells. In a series of papers, this distortion 
was studied and identified as Resonant Mie scattering.24-26 85 
Importantly, it was shown that failure to remove the scattering 
 
distortion from the spectra could lead to apparent shifts in 
positions of absorption bands resulting in wrongly interpreting 
the differences as changes in cellular biochemistry. More 
recently, we developed a correction algorithm to tackle this 
problem that enables the scattering component of the spectrum to 5 
be calculated and removed from the measured spectrum, leaving 
the pure absorption spectrum of the intact cell.27-28 This 
correction algorithm has been used successfully on single cell 
spectra enabling different cell types, including stem-like cells, to 
be separated based on their infrared spectral features.29-30 A 10 
review of the literature, however, shows that other infrared 
studies of stem cell differentiation have not been subjected to any 
form of scatter correction. Krafft et al31 and Bently et al,32 used 
average spectra rather than single cell spectra,33 or used EMSC 
without taking into account resonance effects. It is possible, 15 
therefore, that spectral separation between cell phenotypes may 
be based in-part on changing cell morphology rather than 
exclusive changes in cell chemistry.  In addition, recent studies 
have shown that single cell spectra recorded in transflection mode 
using low-e or metallic substrates can also be subject to 20 
distortion, resulting from the so called electric-field standing 
wave effect.34,35 Although the use of the second derivative33,36 can 
mitigate to some extent against this distortion, it is not fool-proof 
and errors is assignment/classification can still occur.35 In this 
study, we show that FT-IRMS coupled with the RMieS-EMSC 25 
correction algorithm and multivariate analysis can be used as an 
effective tool to investigate the differentiation of human 
pluripotent stem cells, based on the spectral changes associated 
with changing biochemistry alone. Using this methodology, we 
show that it is then possible to observe subtle spectral differences 30 
induced by various different retinoid compounds that reflect real 
biochemical changes within the cells. 
 
Experimental 
 35 
Preparation and analysis of cell cultures  
 
Retinoid Solutions: In preparation for use in cell culture 
experiments, stock solutions of synthetic retinoids (EC23, EC19) 
and all-trans-retinoic acid (ATRA) (Sigma) were prepared in 40 
DMSO (Sigma) to concentrations of 10 mM. Aliquot stock 
solutions were stored at – 80 ºC in the dark.  
 
Tissue Culture: Human pluripotent TERA2.cl.SP12 embryonal 
carcinoma stem cells were maintained under standard laboratory 45 
conditions. In brief, cells were cultured in a humidified 
atmosphere of 5 % CO2 in air at 37 
ºC, in a Sanyo CO2 incubator, 
cultured in DMEM (Sigma) supplemented with 10 % FCS 
(Gibco), 2mM L-glutamine and 100 active units each of penicillin 
and streptomycin (Gibco). Cultures were passaged using acid-50 
washed glass beads (VWR) unless a single-cell suspension was 
required for counting, in which case a 0.25 % trypsin EDTA 
(Cambrex) solution was used. All cultures were handled in 
reduced light conditions, to account for the instability 
(photosensitivity) of ATRA. Cultures intended for flow 55 
cytometry and IR analysis were set up in T25 flasks (BD Falcon). 
After 7 days the cultures were split in a ratio of 1:9, with the 
smaller fraction used for analysis by flow cytometry and the 
larger fixed in 4% formalin solution.  
Flow Cytometry: Flow cytometry analysis was carried out on 60 
live cells using antibodies recognising cell surface markers. The 
expression of markers indicative of the stem cell (SSEA-3 
(University of Iowa Hybridoma Bank) or neural cell (A2B5, 
R&D Systems) phenotype was determined to indicate the status 
of cellular differentiation by TERA2.cl.SP12 cells. Suspensions 65 
of single EC cells of their differentiated derivatives were formed 
by the addition of 1 mL 0.25% trypsin/EDTA solution. The cell 
suspension was divided accordingly for flow cytometry analysis 
and fixing accordingly (see above). Cells were added to a 96-well 
plate as a suspension in wash buffer (0.1 % BSA in PBS) for 70 
incubation with primary (1:10 SSEA-3 and 1:20 A2B5) and 
FITC-conjugated secondary antibody IgM (Sigma, 1:100). 
Labelled cells were analysed in a Guave EasyCyte Plus System 
(Millipore) flow cytometer. Thresholds determining the numbers 
of positively expressing cells were set against the negative 75 
control antibody P3X. 
 
 
Fig. 2 Expression of SSEA-3 (Stem cell) and A2B5 (Neural) markers for 
the DMSO, ATRA, EC19 and EC23 treated TERA2.cl.SP12 cells and the 
untreated control cells after 7 days. 
 
Analysis of the cell surface markers indicative of the status of 5 
stem cell phenotype or commitment toward differentiation were 
assessed by flow cytometry (Fig. 2).  The data show that ATRA 
and EC23 induce the differentiation of TERA2.cl.SP12 EC cells 
by increasing the expression of the neural marker A2B5 and 
reducing the expression of the stem cell marker SSEA3.  Cultures 10 
treated with EC19 retain a high level of SSEA3 and A2B5 
expression is low indicating that these cultures remain largely 
undifferentiated. 
 
FTIR sample preparation 15 
 
Cytospinning onto 1 mm CaF2 plates: All sample and control 
culture solutions were agitated to provide a homogeneous 
solution. 100 microliters of all culture solutions were then 
dispensed into individual labelled cytospinning cuvettes. The 20 
loaded cuvettes were spun at 950 rpm for five minutes firing a 
number of TERA2.cl.SP12 embryonal carcinoma stem cells onto 
the CaF2 substrate window. The micro-slides were left to dry 
overnight, dipped carefully into double distilled water to remove 
any residual salt and left to air dry.  25 
 
Experimental set-up for FTIR 
FT-IR imaging: The infrared data were recorded on a Varian 
670 FTIR spectrometer interfaced with a Varian-620 imaging 
infrared microscope. The microscope was equipped with a 128 × 30 
128 liquid nitrogen cooled MCT focal plane array detector (FPA) 
with a pixel effective size on the sample of 5.5 µm. The infrared 
spectral images were collected in transmission mode (500 scans 
at 4 cm-1 resolution) and the background image was recorded 
from a clean CaF2 slide.  35 
 
Synchrotron FT-IR microspectroscopy: The synchrotron 
infrared microscopy was carried out using the infrared beamline 
(MIRIAM) at the Diamond Light source, Didcot Oxford UK.37 
The data were recorded on a Bruker Vertex 80V vacuum 40 
spectrometer coupled to a Hyperion 3000 infrared microscope. 
The infrared beam from the synchrotron was optimised by 
adjusting the 36x magnification optical condenser on the 
microscope enhancing the lower wavenumber range (1200 - 1000 
cm–1). The aperture was set to 14 × 14 µm2 such that the beam 45 
just covered a single cell on the CaF2 slide. The microscope is 
equipped with a mid-band high sensitivity MCT detector which, 
via the 36x magnification objective used, has an effective area of 
14×14 µm2 at the sample. Both the background and sample 
spectra were recorded at 4 cm–1 spectral resolution and 256 scans. 50 
For each biological replicate approximately 40 cell spectra were 
recorded. 
 
Data pre-processing and chemometrics  
 55 
Pre-processing for FT-IR imaging: An in house function was 
written for and used in MATLAB that identifies individual cells 
within the spectral images collected from sample slides. The 
function also removes spectra from non-mono-layer distributed 
cells and single cell spectra with poor signal to noise. The spectra 60 
obtained from each pixel in a given cell area are averaged to give 
a single unique spectrum for that single cell. All of the mean cell 
spectra were subjected to the RMieS – EMSC correction 
algorithm (20 iterations).25-28 The corrected spectra were then run 
through a noise reduction algorithm, vector normalised and 65 
transformed to the second derivative (11 point Savitsky-Golay 
smoothing, polynomial order 3). The fingerprint region 1000-
1475 cm-1 was analysed after mean centring using principal 
component analysis (PCA) and principal component linear 
discriminant analysis (PC-LDA).  70 
 
Pre-processing for synchrotron single point data: All 
synchrotron collected data with poor signal to noise were 
removed and the remaining spectra corrected using the RMieS – 
EMSC correction algorithm (20 iterations).25-28,38 The corrected 75 
spectra were then run through a noise reduction algorithm, vector 
normalised and transformed to the second derivative (9 point 
Savitsky-Golay smoothing, polynomial order 3). The fingerprint 
region 1000-1475 cm-1 was analysed after mean centring using 
principal component analysis (PCA) and principal component 80 
linear discriminant analysis (PC-LDA).  
 
Statistical Analysis: PCA analysis was performed on all pre-
processed data to generate a new data set consisting of principle 
components (PCs) that contains the spectral variance present in 85 
the original data set.39 These PCs representing the spectral 
variance, were extracted and inputted into the Linear 
Discriminant Analysis (LDA) supervised multivariate algorithm. 
 
It is important to ensure that no noise is being extracted into the 
LDA model as over fitting can occur. To ensure noise was not a 
significant component in the LDA analysis, predicted residual 
sum of squares (PRESS) was used to estimate the predictive 
ability of the PC-LDA model using leave one out (LOO) cross 5 
validation.40 PRESS results reveal the PCs from the PCA analysis 
which have started to contain noise. Also, the number of PCs 
selected contained less than 95 % of the overall spectral variance 
explained. Example scree plots of the percent variance explained 
per PC and PRESS results are provided in the supplementary 10 
notes. PC-LDA models have also been subjected to 10 fold cross 
validation to test the performance of the PC-LDA model 41; see 
supplementary material. 
 
Sample and Control reproducibility: All Samples and controls 15 
have been studied in multiple replicates (generally triplicate) and 
verification for internal consistency of the control replicates was 
undertaken and can be found in the supplementary data. 
 
Results and Discussion 20 
 
Identification and justification of control 
It was necessary to initially dissolve the compounds ATRA, 
EC23 and EC19 in the organic solvent DMSO prior to adding 
them to the aqueous based media solution at the desired 25 
concentration.  DMSO is therefore a vehicle and it was therefore 
necessary to identify any spectral changes effected by DMSO 
itself. Several studies have shown that DMSO can induce 
differentiation of both ES and EC stem cells with key stem cell 
markers, such as Oct-4 being down regulated in gene expression 30 
tests at certain concentrations.42-44 The flow cytometry results in 
this study show that the TERA2.cl.SP12 cells treated with DMSO 
at 10 mM concentration show no significant differences from the 
untreated TERA2.cl.SP12 cells. There was, however, a small 
drop in the SSEA-3 stem cell marker in the DMSO treated cells, 35 
Fig. 2, but not large enough to indicate that differentiation had 
begun to any significant level.  This was consistent with previous 
work reported by Christie et al.14 However, using PC-LDA to 
compare the infrared spectral fingerprints of the untreated and 
DMSO treated TERA2.cl.SP12 cells shows clear spectral 40 
differences are visible at 3, 5 and 7 days (Fig. 3). Accordingly, 
even though no apparent down regulation of the stem cell marker 
(SSEA-3) was observed by flow cytometry for the DMSO treated 
samples, there is clearly a visible cell response to the DMSO in 
the infrared spectra. This difference must be considered for 45 
accurate interpretation of the spectra generated for ATRA and 
synthetic retinoid treated cells to dissect out the affect of the 
DMSO vehicle. DMSO treated samples were therefore selected 
as the control. For the purposes of being concise, only spectral 
data concerning the effects of EC23 treatment of TERA2.cl.SP12 50 
cells over the experimental time periods (3, 5 and 7 days) with 
direct comparisons to the other systems, where appropriate, are 
shown. Full equivalent data relating to ATRA and EC19 can be 
found in the supplementary material.                                                                                                                                                                                       
 55 
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 75 Fig. 3 PC-75 
LDA of control 
(pink) vs. DMSO (black) treated TERA2.cl.SP12 cells at days 3 (a), 5 
(b) and 7 (c) respectively. (7 days 6 PC’s used, 5 days 10 PC’s used, 3 
days 6 PC’s used) 
 80 
Comparison of Control and EC23 treated TERA2.cl.SP12 
cells after 7 days  
Flow cytometric analysis of TERA2.cl.SP12 cells treated with 
EC23 for 7 days indicate induction of differentiation toward the 
neural lineage (Fig. 2).  This is consistent with previous work of 85 
Maltman et al.15 The PCA-LDA plot, Fig. 4a, shows the 
separation between the DMSO and EC23 treated TERA2.cl.SP12 
cells along LDA 1 and is related to the LDA loadings plot, Fig. 
 
4b, which identifies the wavenumbers of absorption bands 
responsible for the separation. 
   Comparison of either the mean spectra or the loadings plot for 
the EC23 treated TERA2.cl.SP12 cells in Fig. 4b show no 
obvious new spectral bands, rather subtle spectral differences that 5 
relate to changes in relative absorption. The increase in spectral 
absorption at ~1060 cm-1 and ~1383 cm-1 assignable to 
polysaccharides and glycoproteins respectively,45 could 
reasonably represent an increase in glycoproteins46-47 and also fits 
with the increase in absorption at ~1468 cm-1 attributed to 10 
spectral absorptions of lipids and proteins45 first described by 
Abaskharoun et al.48 
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Fig. 4 (a) PC-LDA of EC23 (blue) and DMSO (black) treated 
TERA2.cl.SP12 cells at day 7 (8 PCs used) (b) (Lower curves) mean 
spectra of the control and EC23 treated TERA2.cl.SP12 cells, (upper 
curve) LDA 1 loading plot from the EC23 vs. DMSO PC-LDA analysis at 35 
7 days. 
 
This increase in polysaccharide could also indicate increased 
proteoglycan synthesis a known cell protection process invoked 
during differentiation. In addition, extracellular proteoglycan 40 
ligands play a major role in extracellular signalling for 
differentiation.46 The increase in absorption at ~1468 cm-1 45 and 
decreases at ~1392 cm-1,33  1439 cm-1 and 1454 cm-1 45 may 
indicate down-regulation of glycolipid synthesis and up -
regulation of new sphingolipids and gangliosides.49 This is 45 
consistent with major roles identified for sphingolipids such as, 
membrane stabilisers, regulation of apoptosis, cell polarity, 
differentiation of pluripotent embryonic stem cells and part of the 
genome signalling pathways.49 Ganglioside volume is also known 
to increase during neuronal differentiation of embryonal 50 
carcinoma stem cells induced by retinoid acid.50 This would also 
agree with the up-regulation of the A2B5 (neural) marker in Fig. 
2, which is a cell surface ganglioside epitope. Another significant 
difference is the reduced absorption at 1032 cm-1. This band is 
ascribed to glycogen45 and a reduction in its intensity is indicative 55 
of a reduction in glycogen brought about by the need fuel the 
synthesis of new proteins, lipids and nucleic acids during the 
differentiation process. Reduced absorption can also be seen from 
the EC23 treated cells at bands ~1083 cm-1, 1155 cm-1, 1338 cm-1 
attributed to RNA6, carbohydrate and collagen.45 Changes in 60 
spectral absorption seen for the ATRA and EC19 treated 
TERA2.cl.SP12 cells can be seen from in the supplementary data 
and Table 1. 
 
Comparison of Control and EC23 treated TERA2.cl.SP12 65 
cells after 5 days 
Since PC-LDA of the fingerprint region allowed separation of the 
EC23 treated and untreated TERA2.cl.SP12 cells at day 7 the 
investigation was repeated at day 5 to see if: (i) spectral 
differences due to cell differentiation could be identified at this 70 
time point: and (ii) if cell differentiation could be seen at day 5, 
whether the same or different spectral features are responsible for 
the separation (vida infra); see Fig. 5. It was found, as at day 7, 
that separation of the EC23 treated from untreated 
TERA2.cl.SP12 cells could be achieved using PC-LDA, Fig. 75 
5(a). Also see supplementary data for analogous plots for EC19 
and ATRA treated TERA2.cl.SP12 cells. The main absorption 
bands responsible for the separation seen in Fig. 5(a) are 
identified from the loadings plot, Fig. 5(b).  
   In previous work by Heraud et al.33 using FTIR spectroscopy to 80 
distinguish between undifferentiated hESCs and differentiating 
cells at 4 days, the principal spectral differences observed were 
reduced absorption from the fingerprint (1000 - 1450 cm-1) and 
lipid spectral regions (2830 – 2975 cm-1) and increased 
absorption from the amide spectral region (1500 -1700 cm-1). 85 
Reduced absorption at ~1080 cm-1 was assigned to the phosphate 
stretching vibration of RNA33 and had previously been described 
as important in differentiating cells by Notingher and Walsh.51-54 
Notingher et al. suggested that the decrease in RNA observed in 
 
differentiating cells is due to the cells utilising a pool of dormant 
mRNA to synthesise new specific proteins required by the new 
phenotype.52-54 TERA2.cl.SP12 cells treated with EC23 in Fig. 5, 
show a similar drop in absorption at ~1080-84 cm-1 6 along LDA 
1 with increases in absorption in bands at ~1155 cm-1, ~1204 cm-1 5 
and ~1338 cm-1,45 these absorption bands are  
 
 
 
 10 
 
 
 
 
 15 
 
 
 
 
 20 
 
 
 
 
 25 
 
Fig. 5 (a) PC-LDA of EC23 (blue) and DMSO (black) treated 
TERA2.cl.SP12 cells at day 5 (8 PCs used) (b) (Lower curves) mean 
spectra of the control and EC23 treated TERA2.cl.SP12 cells, (upper 
curve) LDA 1 loading plot from the EC23 vs. DMSO PC-LDA analysis at 30 
5 days 
 
assigned to carbohydrates, proteins-amide III and collagen 
respectively. Decreases in absorption of the EC23 treated 
TERA2.cl.SP12 cells assigned to glycogen, nucleic acids, lipids 35 
and proteins can also be seen,33,45 see Table 1. An Increase in 
mean protein absorption at ~1658 cm-1 is also observable for the 
differentiating EC23 TERA2.cl.SP12 cells when compared to the 
control cells, at day 5, see supplementary material. This is in 
agreement with the hypothesis that the differentiating EC23 40 
treated cells at day 5 are using up their glycogen and mRNA 
stores in order to synthesise the new proteins needed for the new 
neuronal phenotype.52,54 Overall spectral absorption decreases in 
RNA/DNA and increases in protein absorption during 
differentiation have also been witnessed by Ami et al.18 in a study 45 
looking at murine embryonic stem cells. Similar spectral changes 
are seen from the EC19 and ATRA treated TERA2.cl.SP12 cells, 
see supplementary data and Table 1. 
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Fig. 6 (a) PC-LDA of EC23 (blue) and DMSO (black) treated 
TERA2.cl.SP12 cells at day 3 (6 PCs used) (b) (Lower curves) mean 
spectra of the control and EC 23 treated TERA2.cl.SP12 cells, (upper 5 
curve) LDA 1 loading plot from the EC23 vs. DMSO PC-LDA analysis at 
3 days 
 
Comparison of Control and EC23 treated TERA2.cl.SP12 
cells after 3 days 10 
The PC-LDA fingerprint region allowed separation of the EC23 
treated and untreated TERA2.cl.SP12 cells at day 5, therefore the 
investigation was repeated at day 3 to determine whether the 
technique is sensitive enough to identify any biochemical 
differences due to the introduction of the retinoids at this earlier 15 
time period (Fig. 6 (a)).  
   It was found, as at days 7 and 5, separation of the EC23 treated 
TERA2.cl.SP12 cells from the control could be achieved using 
PC-LDA, Fig. 6 (a). See supplementary data for analogous plots 
for EC19 and ATRA treated TERA2.cl.SP12 cells. The main 20 
absorption bands responsible for the separation seen in Fig. 6 (a) 
were identified in the loadings plot in Fig. 6 (b). 
   Figure 6(b) shows that the EC23 treated TERA2.cl.SP12 cells 
have decreased absorption bands attributable to glycogen, 
carbohydrates, collagen, glycoproteins, lipids and proteins and 25 
increases in band absorptions for nucleic acids (proteoglycan and 
RNA), carbohydrates, proteins amide and protein-amide III, see 
Table 1. The main spectral differences seen in the loading plot, 
Fig. 6 (b), tend to be above 1400 wavenumbers with the most 
significant spectral difference being the reduction in absorption at 30 
bands ~1439 cm-1, ~1452 cm-1 and 1468 cm-1, relating to proteins 
and lipids,45 see Table 1. These changes may well signify the 
down-regulation of proteins and lipids needed for normal cell 
cycle proliferation. Increases in absorptions attributed to nucleic 
acids (proteoglycan and RNA) and proteins may also signify the 35 
synthesis of new proteins and nucleic acids needed for 
differentiation. Similar changes in absorption are seen for the 
ATRA and EC19 treated TERA2.cl.SP12 cells (See 
supplementary data and Table 1).  
 40 
Comparison of EC23 treated TERA2.cl.SP12 cells after 7, 5 
and 3 days 
All EC23 treated TERA2.cl.SP12 cells can be distinguished from 
control cells at 3, 5 and 7 days respectively. It is, therefore, 
important to determine whether the spectral changes at each time 45 
point are the same or different. Identification of the spectral 
markers as the differentiation process proceeds should provide 
insight into the nature of the changing biochemical processes 
involved in differentiation and this is an area of active current 
investigation.31-33, 51-57 50 
   PC-LDA analysis of the EC23 treated TERA2.cl.SP12 cells at 
3, 5 and 7 days shows clear separation of the three time periods 
(Fig. 7 (a)). Separation is seen for the ATRA TERA2.cl.SP12 
cells between day 7 and days 3 and 5 thus, suggesting that 
between 3 and 5 days after ATRA was added to the 55 
TERA2.cl.SP12 cells, little or no biochemical change has 
occurred. However, PC-LDA results of the control and EC19 
cells at days 3, 5 and 7 (supplementary material), show that the 
control and EC19 cells at days 3 and 7 are spectrally similar. This 
shows more of a cyclic biochemical change in the EC19 treated 60 
and control cells through time. This also coincides with the flow 
cytometry results in Fig. 2, which show that the DMSO and EC19 
treated cells appear to have mainly remained stem cell like at 7 
days. This may suggest that this cyclic biochemical change is a 
product of cells that are still largely in the proliferating cell cycle. 65 
Previous work has shown that the EC19 synthetic retinoid 
compound has a much slower rate to which cells are committed 
to differentiate than ATRA and EC23.14 Results in Fig.2 and the 
PC-LDA results of the EC19 cells at days 3, 5 and 7, would be in 
agreement with this and would suggest that many of the cells 70 
have yet to fully commit to differentiation at 7 days. However, a 
cell reaction to the introduction of the EC19 compound at all time 
periods has been seen when compared to the control cells, see 
supplementary information, which suggests that the cells have 
started on their differentiation pathway to form epithelial cells but 75 
have yet to fully commit to differentiation.  
   Being able to distinguish between the treated TERA2.cl.SP12 
cells and the different spectral absorption changes seen at each 
time point shows that the spectral changes of the treated 
TERA2.cl.SP12 cells are different as the differentiation process 80 
progresses. By monitoring these spectral changes it will be 
possible to identify the spectral markers as the differentiation 
process proceeds. However, later and early time periods may be 
needed to fully investigate the differentiation process of this cell 
line. The spectral absorption increases in Fig. 7(b) for the EC23 85 
treated cells at day 7, are assignable to nucleic acids, 
carbohydrates, glycoproteins and proteins and lipids, whereas the 
decreases in absorbance’s are assigned to glycogen, RNA, 
carbohydrates, protein-amide III and lipids and proteins, see 
 
Table 1 for absorption band assignment. For LDA 2, increases in 
spectral absorbance can be seen for the EC23 treated cells at day 
3 attributed to glycogen, nucleic acids, carbohydrates, collagen 
and amide-amide III, see Table 1.45 Decreases in spectral 
absorption along LDA 2 can be assigned to protein-amide III at 5 
~1311 cm-1, glycoprotein, lipids and proteins, see Table 1.45 
   From the mean spectral differences in Fig. 7 (a) and (b), it can 
be seen that at ~1338 cm-1, ~1383 cm-1 and ~1468 cm-1, there are 
changes in absorbance with respect to time attributable to 
changes in collagen, glycoprotein, protein and lipids.45 Changes 10 
in absorption with respect to time can also be seen at ~1468 cm-1, 
~1454 cm-1, ~1439 cm-1 and ~1383 cm-1 from the ATRA treated 
TERA2.cl.SP12 cells. However, the control and EC19 treated 
TERA2.cl.SP12 cells only show absorption changes with respect 
to time at ~1032 cm-1 and 1236 cm-1 respectively. The increase at 15 
~1468 cm-1 is attributed to absorption of proteins and lipids45 and 
suggests that the ATRA and EC23 treated TERA2.cl.SP12 cells 
are up-regulating new proteins and lipids needed to form the new 
differentiated phenotype. This increase in absorption at ~1468 
cm-1 could therefore be a spectral biomarker of neuronal stem cell 20 
differentiation for this cell line. The increase at ~1236 cm-1 for the 
EC19 treated TERA2.cl.SP12 cells could also indicate the first 
signs of new proteins being synthesised for epithelial 
differentiation and the spectral variability of the control cells may 
be a confirmation of the cells being at different stages of mitosis. 25 
 
 
Table 1. Assigning spectral bands to the loading plot weights  
 
 
 EC 23 EC 19 ATRA ATRA vs. EC 23 ATRA vs. EC 19 EC 23 vs. EC 19 (>) increase spectral  
absorption 
 LDA 1 LDA 1 LDA 1 LDA 1 LDA 1 LDA 1 (<) decrease in spectral  
absorption 
 > 
EC 23 
< 
EC 23 
> 
EC 19 
< 
EC 19 
> 
ATRA 
< 
ATRA 
> 
EC 23 
< 
EC 23 
> 
ATRA 
< 
ATRA 
> 
EC 23 
< 
EC 23 
 
Band Assignments (cm -1) 
Day  
7 
~1061 
~1117 
~1165 
~1308 
~1383 
~1469 
~1032 
~1084 
~1153 
~1338 
~1367 
~1392 
~1439 
~1456 
~1061 
~1082 
~1204 
~1234 
 
~1034 
~1155 
~1304 
~1384 
~1442 
~1468 
 
~1084 
~1155 
~1201 
~1234 
~1315 
 
~1032 
~1063 
~1169 
~1367 
~1381 
~1439 
~1452 
~1468 
~1061 
~1117 
~1171 
~1367 
~1381 
~1450 
~1468 
~1082 
~1153 
~1201 
~1338 
~1396 
 
~1084 
~1180 
~1201 
~1394 
~1452 
~1466 
~1059 
~1117 
~1155 
~1171 
~1232 
~1367 
~1385 
~1439 
~1061 
~1313 
~1381 
~1404 
~1412 
~1450 
~1468 
~1084 
~1155 
~1171 
~1203 
~1338 
~1390 
~1419 
~1439 
 
 
1025: glycogen.45 
1032: glycogen and one of 
the triad peaks of nucleic 
acids.45, 66  
1051: C-O-C stretching of 
DNA and RNA.45 
1062: polysaccharide-
cellulose and one of the triad 
peaks of nucleic acids,45 
Ribose RNA64 and 
proteoglycans.50 
1068: Stretching C-O 
ribose.45 
1084: Stretching PO2
- 
symmetric of DNA and 
RNA.6,45,66 
1117: C-O stretching 
vibration of C-OH group of 
ribose (RNA).45 
1126: DNA/RNA.68 
1155: C-O stretching 
vibration from 
carbohydrates.45 
1173: Non-hydrogen-bonded 
stretching mode of C-OH 
groups (carbohydrates).45 
1204: Vibrational modes of 
collagen proteins-amide III 
and polysaccharides 45 
1236: Amide III band PO2 - 
of nucleic acids.45 
1312: Amide III band 
components of proteins.45 
1338: CH2 wagging of 
collagen.45,67 
1367: Stretching C-O, 
deformation C-H, 
deformation N-H.45 
1380: Stretching C-O, 
deformation C-H, 
deformation N-H.45 
1385: CH3 stretching
45 and 
glycoproteins.53 
1390: Methyl, methylene and 
carboxylate groups of 
lipids.33 
1396: Symmetric CH3 
bending of the methyl groups 
of proteins.45 
1404:CH3 asymmetric 
deformation 
1412-1414: Stretching C-N, 
deformation N-H, 
deformation C-H.45 
1419: Deformation C-H.45 
1444: Changes in lipids and 
fatty acids.45 
1451: Asymmetric CH3 
bending modes of the methyl 
groups of proteins.45 
1454: CH3 scissoring of 
mainly lipids and asymmetric 
methyl deformation.45, 68 
1458: CH3 of collagen.
45 
1465-1468: CH2 bending 
vibration (lipids and 
proteins).45 
1470:CH2 bending of the 
methylene chains in lipids.45
 
Day 
 5 
~1026 
~1155 
~1200 
~1311 
~1472 
~1034 
~1051 
~1065 
~1084 
~1126 
~1367 
~1387 
~1439 
~1452 
~1466 
~1026 
~1061 
~1155 
~1203 
~1335 
~1392 
~1439 
~1051 
~1068 
~1124 
~1234 
~1369 
~1383 
~1412 
~1450 
~1469 
~1157 
~1201 
~1410 
~1032 
~1051 
~1065 
~1084 
~1234 
~1365 
~1381 
~1437 
~1452 
~1466 
~1026 
~1155 
~1196 
~1315 
~1448 
~1061 
~1084 
~1173~
1203 
~1336 
~1367 
~1387 
~1456 
~1051 
~1066 
~1084 
~1126 
~1173 
~1236 
~1387 
~1452 
~1469 
~1030 
~1061 
~1076 
~1155 
~1201 
~1331 
~1365 
~1381 
~1394 
~1441 
~1119 
~1173 
~1194 
~1313 
~1404 
~1410 
~1450 
~1032 
~1061 
~1153 
~1203 
~1336 
~1367 
~1379 
~1392 
~1441 
~1469 
Day 
 3 
~1063 
~1082 
~1159 
~1173 
~1203 
~1232 
~1410 
 
~1032 
~1315 
~1365 
~1381 
~1439 
~1456 
~1468 
~1061 
~1201 
~1076 
~1032 
~1051 
~1084 
~1151 
~1336 
~1367 
~1381 
~1390 
~1439 
~1452 
~1468 
~1059 
~1082 
~1157 
~1201 
~1232 
~1375 
 
~1034 
~1051 
~1367 
~1385 
~1468 
~1159 
~1173 
~1201 
~1232 
~1410 
~1032 
~1194 
~1381 
~1394 
~1439 
~1456 
~1468 
~1032 
~1051 
~1082 
~1153 
~1336 
~1381 
~1389 
~1410 
~1439~
1452 
~1468 
~1061 
~1200 
~1232 
~1313 
 
~1084 
~1155 
~1173 
~1205 
~1232 
~1336 
~1369 
~1410 
~1450 
~1466 
~1061 
~1198 
~1315 
~1379 
~1394 
~1458 
~1473 
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Fig. 7 (a) PC-LDA of EC23 treated cells at 3 (black), 5 (blue) and 7 
(green) days, 8 PCs used (b) Mean spectra of the EC23 treated 
TERA2.cl.SP12 cells at days 3, 5 and 7 (bottom) and the LDA 1 loading 
plot from the PC-LDA analysis of EC23 at days 3, 5 and 7 (top) (c) LDA 30 
2 loading plot from the PC-LDA analysis of EC23 at days 3, 5 and 7. 
 
   Previously it has been suggested that embryonic stem cells have 
a higher nucleus to cytoplasm ratio than that of differentiating 
cells.18 This is because it is believed that as the cells differentiate 35 
the nucleus shrinks causing a reduction in nucleic acid absorption 
and an increase in protein and lipid absorption from the larger 
cytoplasm.18 To see if the TERA2.cl.SP12 cells follow a similar 
pattern, the nucleus to cytoplasm ratio was calculated using the 
ratio of the 1080 (nucleus) to 1468 (cytoplasm) bands Fig. 8. 40 
Results in Fig. 8, are consistent with previous work by Notingher 
et al.18, 52-54 however, the nucleus to cytoplasm ratio results for 
the EC19, ATRA treated and control TERA2.cl.SP12 cells are 
not, see supplementary data. Heraud et al. has also looked at 
specific spectral absorbance bands in order to try and explain 45 
stem cell differentiation. Work by Heraud showed that hESC 
have increased carbohydrate and lipid absorptions at bands ~1155 
cm-1 and ~2920 cm-1 respectively when compared to that of 
differentiating cell populations.33 In Fig. 9, it can be seen that the 
EC23 treated cells are in agreement with the results seen by 50 
Heraud for the carbohydrate absorption band at ~1155 cm-1, 
however, there was an increase in absorption at ~2920 cm-1 when 
compared to that of the control cells. In the case of the ATRA 
treated TERA2.cl.SP12 cells, Fig 9(b) there’s a slight increase in 
absorption at ~1155 cm-1 and a decrease at ~2920 cm-1 when 55 
compared to the control cells in agreement with the results seen 
by Heraud thus, highlighting a possible difference in biochemical 
response of the TERA2.cl.SP12 cells when ATRA and EC23 are 
introduced for 7 days.  
 60 
Fig. 8 Bar graph representing the nucleus to cytoplasm ratio for the EC23 
treated TERA2.cl.SP12 cells at days 3, 5 and 7 
 
 
(a) 
(b) 
 
Fig. 9 (a) Bar graph representing the mean absorption at band 1155 cm 
-1
 
for the control cells and all retinoid treated TERA2.cl.SP12 cells at day 7  
(b) Bar graph representing the mean absorption at band 2920 cm 
-1
 for the 
control cells and all retinoid treated TERA2.cl.SP12 cells at day 7.  
 5 
Comparison of EC23 and ATRA treated TERA2.cl.SP12 cells 
Previous work15 has shown that the EC23 and ATRA treated 
TERA2.cl.SP12 cells produce very similar protein profiles during 
the cell differentiation process and therefore, a close functional 
relationship. However, subtle but significant difference in the 10 
response of the TERA2.cl.SP12 cells to both ATRA and EC23 
was seen, primarily the cellular retinoic acid binding protein 1 
(CRABP1).15 Christie et al. also looked at the similar biological 
effects the two retinoids had on the TERA2.cl.SP12 cells and 
their study showed that the EC23 retinoid induced the production 15 
of neural tissue at a similar or possibly increased level to that 
seen when using ATRA.14 The cells treated with EC23 and 
ATRA at 3, 5 and 7 days were compared to see if these subtle 
differences could be also identified in the infrared spectral 
fingerprints, Fig. 10.  20 
   Even though both ATRA and EC23 are known to induce cell 
differentiation to form the same cell type, the FT-IR results, Fig. 
10, show that there are measurable spectral differences between 
the EC23 and ATRA treated TERA2.cl.SP12 cells at the same 
relative time points and this is consistent with previous 25 
observations seen using other techniques.14-15 This could result 
from a number of possibilities: (i) the retinoid treated 
TERA2.cl.SP12 cells follow different differentiation pathways: 
or, (ii) the retinoid treated TERA2.cl.SP12 are following the same 
differentiation pathway but staggered relative to each other due to 30 
the differences in each initiators ability to start the differentiation 
process.  
   To test these possibilities, ATRA and EC23 treated 
TERA2.cl.SP12 cells were compared at all time periods, Fig. 11 
(a). The score plot results in Fig. 11 (a) appear to show that the 35 
ATRA and the EC23 treated cells at days 3 and 5 are spectrally 
similar as they have both merged into a single cluster, whereas at 
day 7, there are significant spectral differences between the 
ATRA and EC23 treated cells. However, it has been shown in 
Fig. 10, that there are spectral differences between the ATRA and 40 
EC23 treated cells at both 3 and 5 days. Therefore, this cluster 
formation of the treated cells at days 3 and 5 may be a result of 
the spectral differences at day 7 being large and the spectral 
differences at days 5 and 3 being subtle, but still significant. 
Spectral differences between the ATRA and EC23 treated 45 
TERA2.cl.SP12 cells can be seen in Fig.12 (a) and (b).  
 
 
  
 50  50 
  
  
  
  
 55  55 
  
  
  
  
 60 
 
 
 
 
 65 
 
 
 
 
 70 
  
Fig. 10 PC-LDA of EC23 (blue) and ATRA (green) treated 
TERA2.cl.SP12 cells at (a) 7, (b) 5 and (c) 3 days (7 days 6 PC’s used, 5 
days 10 PC’s used, 3 days 6 PCs used).  
 75 
The score plot results in Fig. 11 (b) show the ATRA treated cells 
at days 3 and 5 to be spectrally similar; this is in agreement with 
the PC-LDA results of the ATRA treated cells at days 3, 5 and 7 
days found in the supplementary material. The EC23 treated cells 
at days 3 and 5 can be separated from the ATRA cell cluster. 80 
Coupling this with the fact that the ATRA treated cells at days 3 
and 5 have shown reduced biochemical differences when 
compared to the control cells, see supplementary material, and 
the ATRA treated cells at days 3 and 5 are spectrally similar, this 
may suggest that EC23 induces differentiation of the 85 
TERA2.cl.SP12 cells to begin more rapidly than ATRA and is 
subsequently further on down the differentiation pathway at days 
3 and 5 than the ATRA treated at the same time periods. 
  
Fig. 11 (a) PC-LDA of EC23 vs. ATRA at days 3, 5 and 7 (EC23 cells: 
day 3 (black), day 5 (pink), day 7 (blue), ATRA cells: day 3 (green), day 
5 (cyan) and day 7 (red) (14 PCs used)) (b) PC-LDA of EC23 vs. ATRA 
at days 3 and 5 days (EC23 cells: day 3  (black), day 5 (blue), ATRA 5 
cells: day 3 (green), day 5 (red) (15 PCs used). 
 
At day 7 though, there are large spectral differences seen between 
the differently treated TERA2.cl.SP12 cells in both Fig 10 and 
11. Results in Fig. 10 and 11 could therefore be confirmation that 10 
at 7 days, EC23 induces a different differentiation pathway 
altogether to that of ATRA, this would be in agreement with 
results seen in Fig. 9. However, one can also not rule out that 
both ATRA and EC23 are both inducing the differentiation of the 
TERA2.cl.SP12 cells down the same biological pathway, but 15 
slightly staggered due to their ability in starting the differentiation 
process. In future studies the spectral changes of the ATRA and 
EC23 treated cells will be monitored over a longer time period to 
confirm whether EC23 induces the TERA2.cl.SP12 cells down a 
different biological pathway when compared to the natural 20 
retinoid ATRA. 
   LDA 1, Fig. 12 (a), separates the EC23 treated TERA2.cl.SP12 
cells at day 7 from the ATRA treated cells at day 7. The primary 
spectral differences can be attributable to absorption increases for 
the EC23 treated cells at day 7 in polysaccharide-cellulose, 25 
proteoglycan and proteins and lipids and decreases in glycogen, 
RNA, protein-amide III and lipid absorption. LDA 2, Fig. 12 (b), 
separates the ATRA and EC 23 treated cells at day 7 from the 
treated cells at days 5 and 3.  
 30 
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Fig. 12 (a) Mean spectra and LDA 1 loading plot of the EC23 and ATRA 
treated cells at 3, 5 and 7 days (b) Mean spectra and LDA 2 loading plot 
of the EC23 and ATRA treated cells at 3, 5 and 7 days.  50 
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 60 
 
Fig. 13 Mean spectra of EC23 and ATRA at 3 and 5 days (EC23 cells: 
day 3 (black), day 5 (blue), ATRA cells: day 3 (green), day 5 (red). 
 
Here the main spectra differences can be attributable to a 65 
decrease in absorption for the treated cells at day 7 in RNA, 
carbohydrate and lipid absorption and increases in protein-amide 
III proteoglycan and protein lipid (Table 1). This may again 
suggest that as the ATRA and EC 23 treated TERA2.cl.SP12 
 
cells start to differentiate they use up their mRNA stores in order 
to synthesise new specific proteins required by the new neuronal 
phenotype being produced. The spectral absorption increase at 
~1204 cm-1 attributed to proteins-amide III,45 may also be a 
spectral biomarker of neural differentiation for this cell line, 5 
along with the increase in absorption at 1468 cm-1. If this were 
the case then it would suggest that the ATRA treated cells were a 
step further on in the differentiation process than the EC23 
treated TERA2.cl.SP12 cells at the day 7 time period. By looking 
at the data from both the ATRA and EC23 treated 10 
TERA2.cl.SP12 cells at later time periods these spectral 
biomarkers could be confirmed. 
  Interestingly, when comparing the mean spectrums of both 
ATRA and EC23 at days 3 and 5, Fig. 13, there was a mean 
spectral reduction in absorption at band ~1383 cm-1 attributed to 15 
glycoproteins32 from all treated cells except from the ATRA cells 
at day 3. The score plot results in Fig. 11 (b) suggest that the 
ATRA treated cells at day 3 have the least spectral change 
therefore, this reduced absorption at ~1383 cm -1 could signify the 
start of neuronal differentiation. Also in Fig. 13, increases in 20 
spectral absorption with respect to time can be seen at ~1410 cm-1 
attributed to stretching C-N, deformation N-H, deformation C- 
H.45 
 
Comparison of the EC23 and ATRA treated TERA2.cl.SP12 25 
cells with the EC19 treated TERA2.cl.SP12 cells 
 FT-IRMS coupled with PC-LDA has been able to discriminate 
between the ATRA and EC 23 treated cells showing that although 
they both differentiate EC cells to form neurons, there are 
significant differences in the two differentiating pathways. 30 
However, as both of these retinoids induce the differentiation of 
EC cells to produce neurons, it was necessary to test whether 
there is similarity between the ATRA and EC23 treated 
TERA.cl.SP12 cells.  Further, can the neuronal pathway be 
distinguished from epithelial differentiation? To investigate 35 
further, the data from the ATRA and EC23 cells were classed as 
the same sample group and compared with the data from the 
EC19 treated cells using PC-LDA. PC-LDA analysis was 
performed for all time periods (Fig. 14 (a)). 
   Epithelial and neural differentiation can be classified after 7 40 
days using spectral IR fingerprint (Fig. 14(a)). There was also 
reasonable classification at 5 and 3 days consequently suggesting 
that neural and epithelial differentiation may have started to begin 
as early as 3 days. 
 45 
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Fig. 14 PC-LDA analysis of ATRA, EC23 and EC19 treated 80 
TERA2.cl.SP12 cells where two groups are stipulated at 7 (a), 5 (b) and 3 
(c) days (10 PCs extracted from the PCA analysis for 7 days, 8 PCs used 
for 5 days and 10 PCs used for 3 days). EC19 (black) cells epithelial 
differentiation and (blue and green) EC23 treated cells and ATRA 
respectively, neuronal differentiation (d) Mean spectra of the ATRA, 85 
EC23 and EC19 treated TERA2.cl.SP12 cells and the LDA 1 loading plot 
from the neuronal vs. epithelial PC-LDA analysis at 7 days. 
 
Therefore, even though there are spectral differences seen 
between the ATRA and EC23 treated cells at each time period, 
there are still significant similarities between the two differently 
treated TERA.cl.SP12 cells. The absorption bands that 
contributed the most to the separation seen could potentially be 5 
spectral biomarkers of both neuronal and epithelial 
differentiation. The mean spectra and LDA 1 loading plot from 
the day 7 treated cells can be seen in Fig.14 (b). LDA 1, shows a 
reduction in absorbance for the neuronal differentiating cells in 
proteoglycan, carbohydrate, stretching C-O, deformation C-H, 10 
deformation N-H, methyl, methylene and carboxylate groups of 
lipids, deformation C-H and from changes in lipids and fatty 
acids at ~1439 cm-1,33,45,50 (Table 1). Increases in absorption 
intensity of the neuronal differentiating cells can be seen from 
proteins-amide III and polysaccharides, proteins-amide III at 15 
~1312 cm-1, CH3 scissoring of mainly lipids and asymmetric 
methyl deformation lipids and from proteins and lipids at ~1468 
cm-1.45 The spectral differences shown in Fig. 14 (b) may be an 
indication that the neuronal differentiating cells are using up 
carbohydrate stores in order to synthesise the new proteins 20 
needed for the neuronal phenotype, also lipids and proteoglycan 
absorption is falling which again may indicate the down-
regulation of glycolipid synthesis and up-regulation of new 
sphingolipids and gangliosides.49 Interestingly, both the ATRA 
and EC23 treated TERA2.cl.SP12 cells at day 7 have increased 25 
absorptions at bands ~1204 cm-1 and ~1468 cm-1 when compared 
to the EC19 treated cells, this is in agreement with the results 
shown in Fig.12 thus, suggesting that these absorption bands may 
be potential biomarkers of neuronal differentiation. 
 30 
Comparison of the EC23, EC19 and ATRA treated 
TERA2.cl.SP12 cells at 7 days 
Previous research has demonstrated that the EC19 treated 
TERA2.cl.SP12 cells not only produce epithelial cells, but also a 
small number of neuronal cells when inducing differentiation.14 35 
To see if the FT-IR data confirms this, PC-LDA analysis was 
performed of the ATRA, EC23 and EC19 treated cells at 7 days, 
where three individual group classes are stipulated (Fig. 15 (a)). 
The score plot results in Fig. 15 (a), tends to support this 
independently verified observation. 40 
   The data results in Fig. 15 (a), may also suggest that the EC23 
synthetic retinoid is capable of inducing the differentiation of a 
proportion of TERA2.cl.SP12 cells down an epithelial route. This 
is also in agreement with the score plot results from EC19 vs. 
EC23 at day 7, see supplementary notes. In LDA 1 Fig. 15(b), 45 
increases in spectral absorption intensity can be seen for the 
ATRA treated cells at day 7, these can be attributed to RNA, 
carbohydrate at ~1155 cm-1, proteins-amide III at ~1204 cm-1 and 
proteins-amide III at ~1312 cm-1.6,45 Decreases in absorbance can 
be seen from absorption bands attributed to proteoglycan at 1061 50 
cm-1 and lipids and proteins45,50 (Table 1). It’s clear from LDA 1, 
Fig. 15 (b), that the main spectral differences between the ATRA 
and the EC19/EC23 treated TERA2.cl.SP12 cells is the large 
increases in absorption at ~1204 cm-1 and ~1084 cm-1 form the 
ATRA treated cells, associated with proteins-amide III and RNA 55 
respectively. Results from LDA 1 are similar to those seen in Fig. 
12(a) where the ATRA and EC23 treated cells were characterised 
at day 7. LDA 2 separates the neuronal from the epithelial 
differentiating cells and not surprisingly the loading plot is very 
similar to the loading plot seen in Fig. 14(b); Comparisons of 60 
ATRA, EC23 and EC19 at each time period have been 
undertaken and can be found in the supplementary data. 
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Fig. 15 (a) PC-LDA analysis of ATRA (green), EC23 (blue) and EC19 
(red) treated cells where three groups are stipulated at day 7 (8 PCs used) 
(b) Mean spectra of ATRA, EC19 and EC23 treated TERA2.cl.SP12 cells 
and LDA 1 loading plot. Separation along LDA 1 separates the ATRA 
and EC 23 treated cells (c) Mean spectra of ATRA, EC19 and EC23 5 
treated TERA2.cl.SP12 cells and LDA 2 loading plot. Separation along 
LDA 2 separates the ATRA and EC23 cells from the EC19 treated cells 
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Fig. 16 PC-LDA analysis of EC23 (blue) treated cells and the control 
(black) cells at days 7 (a), 5 (b) and 3 (c). 35 
 
Comparison of Control and EC23 treated cells after 7 days 
using Synchrotron FT-IRMS 
Synchrotrons provide a highly collimated beam of light, which 
can be in the order of a 100-1000 times brighter than traditional 40 
sources.23,31,32 The IR region of the emitted synchrotron radiation 
can be directed into a benchtop FT-IRMS and used as a source 
instead of conventional blackbody sources.58 This high brightness 
of synchrotron sources enables much smaller regions to be 
probed with an acceptable Signal to Noise ratio (S/N) thus, 45 
greater spatial resolution approaching the diffraction limit can be 
achieved.32,59-62 To see if there is consistency between data 
collected using synchrotron FT-IRMS and the data collected 
using the benchtop FT-IR imaging instrument with an FPA 
detector, data was recollected from the same EC23 samples and 50 
DMSO control samples at the Diamond Light Source and 
subjected to the same analysis as for the array detection. 
Separation from control and the EC23 treated TERA2.cl.SP12 
cells were seen at days 3, 5 and 7 (Fig. 16). 
      Separation of the data collected synchrotron facility is 55 
observable at all three time periods. To determine whether the 
separation observed using a synchrotron source mirrors that of 
the FT-IR imaging, mean spectra and loadings plots were 
compared and can be seen in Fig. 17. 
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Fig. 17 Comparison of mean spectra and LDA 1 loading plots for 
synchrotron and FT -IRMS imaging generated data for EC23 treated 
TERA2.cl.SP12 and control cells at 7 (a), 5 (b) and 3 (c) days (Imaging 
(top) synchrotron (bottom)) 20 
 
When comparing the loading plots in Fig. 17, clear similarities 
can be seen between the data collected using an FT-IRMS array 
detector and the data collected at the synchrotron facility. This 
therefore, shows consistency between the two types of Infrared 25 
spectroscopy analytical techniques. However, some spectral 
differences can be seen. An explanation for this could be the 
number of spectra recorded using the two different types of 
instrumentation. At the synchrotron facility, 311 single cell 
spectra were recorded when the EC23 treated cells were 30 
compared against the control cells, whereas 1881 cell spectra 
were collected using the array detector for the same comparison. 
This greater number of cell spectra recorded will build a better 
picture of the spectral differences between the two different types 
of treated cells and a low number of spectra may not be sufficient 35 
enough to fully explain the cell cycle i.e. the spectral variations 
due to where the cells are within the cell cycle. Studies by both 
Flower29 and Boydsten-White have explained the spectral 
heterogeneity seen when collecting data from single cells. This 
spectral heterogeneity is a product of the cell cycle with the S 40 
phase producing the most heterogeneous spectra while phases G1 
and G2, show a relatively small variability.63 Therefore, a low 
number of single cell spectra recorded could mean that there is a 
bias included where more cells from one phase of the cell cycle 
are spectrally represented than another. Nevertheless, moderate 45 
reproducible separation was observed when comparing the results 
produced by the two different types of instrumentation. 
Therefore, even though there is an S/N advantage when using 
synchrotron light as a source, S/N rivalling that seen at a 
synchrotron facility can be reproduced when using an array 50 
detector.59  
 
Summary and Conclusions 
The results of this study have shown that FT-IRMS is an effective 
tool that can distinguish between stem cells and their 55 
differentiating derivatives without the need for fluorescent or 
magnetic biomarkers. However, the use of both appropriate 
substrates and scatter correction algorithms is essential, with the 
result that the spectra observed are indeed indicative of the 
cellular biochemistry occuring and are not distorted by either 60 
scattering or electric filed standing wave effects. With the 
addition of multivariate chemometric algorithms, pluripotent 
stem cells can be characterised from their induced derivatives 
based on the spectral differences thus, highlighting the potential 
of FT-IRMS in finding spectral biomarkers of differentiation in a 65 
non-invasive and label free manner. The ability to characterise 
the retinoid treated TERA2.cl.SP12 cells at each time period has 
also shown the potential that FT-IRMS has in being able to 
monitor the progression of stem cell differentiation. Potentially, 
this could mean that FT-IRMS can be used as a quick screening 70 
tool in future stem cell therapy for highlighting the location of 
undifferentiated cells before implantation thus, reducing the risk 
of tumour formation. The results from this study have also shown 
that stem cell differentiation can be seen at earlier time periods 
than when using more traditional techniques used to monitor 75 
these effects.1,2,5 In respect to these positive findings, it can be 
predicted that the biological response of stem cells to small 
molecules such as retinoids could be observed at even earlier time 
periods. This investigation has also confirmed findings from a 
previous study where distinct differences in the response of the 80 
TERA2.cl.SP12 cells were seen when the retinoid ATRA and 
synthetic retinoid EC23 were added.5 By monitoring the spectral 
changes of the TERA2.cl.SP12 cells over time, we hypothesise 
that the ATRA and EC23 treated TERA2.cl.SP12 are likely to be 
following alternative differentiation pathways and possibly 85 
producing different types of neurons; conclusions that have not 
been previously drawn. However, to understand this process 
fully, earlier and later time periods will need to be investigated in 
greater detail, which is as part of our future work. Although, 
 
significant differences in the response of the TERA2.cl.SP12 
cells can be seen in the results, PC-LDA has been able to show 
the spectral similarities of the TERA2.cl.SP12 cells 
differentiating to produce neural cells when compared to the cells 
treated with the synthetic retinoid EC19. Flow cytometry results 5 
in Fig. 2 suggest that at day 7, the EC19 treated TERA2.cl.SP12 
cells have yet to fully commit to the differentiation process. 
However, results in this study have been able to characterise the 
EC19 treated cells from the control cells at all time periods 
therefore, this suggests that the retinoid is having some form of 10 
biological effect on the TERA2.cl.SP12 cells, even though the 
majority of treated cells have yet to down-regulate the SSEA-3 
stem cell marker. Spectral ratios have also been produced that 
look to explain the biological processes of the cells as they 
differentiate. The results in this study show the data for the EC23 15 
treated cells at day 7 are in agreement with the reduced nucleus to 
cytoplasm ratio as differentiation progresses, previously 
explained by Notingher. However, this was not the case for the 
ATRA and EC19 treated cells, which showed more of a 
correlation to previous work by Heraud.33 20 
   Separation of the EC23 treated and the control TERA2.cl.SP12 
samples has also been produced with data recorded at a 
synchrotron facility. Loading plot results from synchrotron data 
closely resembled the results produced from the spectral images. 
The data produced indicate that the two analytical techniques 25 
used are comparable even though a much larger number of cell 
spectra were collected when using FT-IRMS coupled with an 
array detector. This highlights the potential of spectral imaging 
first described by Krafft et al.31 FT-IRMS spectral imaging can 
readily obtain much more spectra, quicker and to a comparable 30 
quality to data recorded at a synchrotron facility. This is 
advantageous for single cell analysis as a high number of cell 
spectra are needed to fully explain the cell cycle.29 It should be 
pointed out though that for sub cellular imaging, the synchrotron 
still enjoys a significant advantage. 35 
   To conclude, in this study infrared microspectroscopy has been 
used to characterise and monitor stem cell differentiation over 
time. Infrared spectral imaging can be employed as an efficient 
rapid approach that is reproducible, does not require time 
consuming sample preparation methods, and is cost effective. 40 
When coupling infrared microspectroscopy with chemometric 
methods, the status of the stem cell phenotype and differentiation 
can be assessed without the need for potentially harmful 
biomarkers being introduced. Spectral loadings also provide an 
insight into the macromolecule changes within the cells during 45 
the differentiation process. Infrared spectra can also be used to 
provide information on the complexes biological processes 
involved in the cell cycle and differentiation. 
   Although previous studies22,36 have used infrared 
microspectroscopy to monitor the spectral fingerprint of stem 50 
cells during the differentiation process, in this study we have 
shown that we are able to monitor the differentiation process of 
the cells, as well as the biochemical changes of the pluripotent 
stem cells through time without attendant aberrations or errors. 
Indeed, we have also shown that by having control cells at the 55 
same period as differentiating, we are able to dissociate the 
biochemical changes of the pluripotent cells from spectral 
differences. This, therefore, means that any biochemical changes 
observed between differentiating cells and control stem cells at 
the same time period are only due to differentiation and we 60 
expect that the protochols we have employed will be become 
standard methodology to support robust and reliable studies of 
this type. 
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